These findings highlight nannocystin Ax’s dual role in targeting both proliferative (via eEF1A-mediated cyclin D1 suppression) and metastatic (via EMT inhibition) pathways, supporting it as a promising multitargeted agent against aggressive cancers. The gene discussed is EEF1A1; the disease is cancer.